A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
CONCLUSION: TAS-115 appears to demonstrate anti-tumor activity and acceptable tolerability in CRPC patients with bone metastases.PMID:34493431 | DOI:10.1016/j.clgc.2021.07.013
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Nobuaki Matsubara Hirotsugu Uemura Satoshi Nagamori Hiroyoshi Suzuki Hiroji Uemura Go Kimura Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | Drugs & Pharmacology | Japan Health | Oral Cancer | PET Scan | Prednisone | Prostate Cancer | Study | Taxotere